Last reviewed · How we verify
Dl-Tertatolol (TERTATOLOL)
Dl-Tertatolol (generic name: TERTATOLOL) is a tertatolol drug. It is currently in Phase 2 development.
Tertatolol works by binding to and activating the beta-3 adrenergic receptor, which is involved in regulating various physiological processes.
Dl-Tertatolol is a small molecule with synonyms including ARTEX, ARTEXAL, PRENALEX, SE-2395, TERTATOLOL, and TERTATOLOL. Its modality is classified as a small molecule.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TERTATOLOL |
|---|---|
| Drug class | tertatolol |
| Target | 5-hydroxytryptamine receptor 1A, Beta-3 adrenergic receptor, 5-hydroxytryptamine receptor 1A |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 2 |
Mechanism of action
Think of it like a key fitting into a lock. Tertatolol is the key that fits into the beta-3 adrenergic receptor, a type of lock on cells. When the key fits into the lock, it triggers a response that helps regulate things like heart rate, blood pressure, and metabolism.
Approved indications
Common side effects
Key clinical trials
- Accuracy of Digital Mandibular Repositioning in Occlusal Reconstruction for Patients With Disc Displacement (NA)
- The Effectiveness of Different Therapeutic Jaw Position Determining Methods in Repositioning Splint Therapy for Temporomandibular Joint Disk Displacement Without Reduction：A Randomized Controlled Clinical Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dl-Tertatolol CI brief — competitive landscape report
- Dl-Tertatolol updates RSS · CI watch RSS
Frequently asked questions about Dl-Tertatolol
What is Dl-Tertatolol?
How does Dl-Tertatolol work?
What is the generic name of Dl-Tertatolol?
What drug class is Dl-Tertatolol in?
What development phase is Dl-Tertatolol in?
What does Dl-Tertatolol target?
Related
- Drug class: All tertatolol drugs
- Target: All drugs targeting 5-hydroxytryptamine receptor 1A, Beta-3 adrenergic receptor, 5-hydroxytryptamine receptor 1A
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing